Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.

Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/Acne inversa / C.C. Zouboulis, H. Hansen, R.D. Caposiena Caro, G. Damiani, I. Delorme, J.C. Pascual, Z. Reguiai, A. Trigoni, E. Vilarrasa, F. Alfageme Roldan. - In: DERMATOLOGY. - ISSN 1018-8665. - 236:1(2020), pp. 25-30. [10.1159/000503606]

Adalimumab dose intensification in recalcitrant hidradenitis suppurativa/Acne inversa

G. Damiani;
2020

Abstract

Background: Adalimumab is the only approved compound for the treatment of adult patients with moderate-to-severe hidradenitis suppurativa (HS) who did not respond to a systemic classical treatment. Despite its significant short- and long-term efficacy, a percentage of patients do not respond sufficiently. Moreover, some primary responders experience a response loss with time. Objective: To analyse the effectiveness of adalimumab dose intensification in HS patients. Methods: A case series of adalimumab 80 mg/week subcutaneously (s.c.) compassionate use in patients with HS, who did not respond sufficiently or in primary responders with progressive response loss to the registered adalimumab dose of 40 mg/week s.c. Patients were collected and evaluated retrospectively. Patients' data were extracted from medical records. Results: The 14 patients collected were Caucasian with HS of Hurley stage II-III and moderate or severe International HS Severity Score System (IHS4) stage. Adalimumab dose intensification significantly improved IHS4 score, Pain Index, HS-Physician Global Assessment, pain, and Cardiff Dermatology Life Quality Index. Two young female patients with HS and Crohn's disease developed psoriatic lesions during the treatment with adalimumab 80 mg/week s.c. Conclusion: An enhanced level of effectiveness was assessed in the majority of the HS patients treated with adalimumab dose intensification (80 mg/week s.c.). Larger studies are required to evaluate this observation.
Acne inversa; Adalimumab; Hidradenitis suppurativa; Intensification; Treatment; Adalimumab; Adult; Dermatologic Agents; Dose-Response Relationship, Drug; Female; Hidradenitis Suppurativa; Humans; Male; Middle Aged; Severity of Illness Index; Young Adult
Settore MED/35 - Malattie Cutanee e Veneree
2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
zouboulis2019-3.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 315.05 kB
Formato Adobe PDF
315.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/788095
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 44
social impact